Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × COVID-19 × Interleukin-7 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphopenia 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Lymphoma, B-Cell 1 Carcinoma, Transitional Cell 1 COVID-19 1 Breast Neoplasms 1

Interventions

Hydroxychloroquine 3 Standard of Care 2 COH04S1 COVID-19 vaccine 2 Azithromycin 2 tocilizumab 1 palbociclib 1 ogalvibart 1 monalizumab 1 crexavibart 1 cilgavimab and tixagevimab drug combination 1 avdoralimab 1 XAV-19 1 Specimen Handling 1 Sodium Chloride 1 Radiotherapy 1 Medical Marijuana 1 Losartan 1 Janus Kinase Inhibitors 1 Ivermectin 1 Interleukin-7 1 HuMax-IL8 1 Gelsolin 1 CVnCoV COVID-19 vaccine 1 COVID-19 Vaccines 1 BNT162 Vaccine 1 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1 1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04426201 2024-04-11

ILIAD-7-US-O

Revimmune

Phase 2 Terminated

COVID-19, Lymphopenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡